Patients prescribed ≥100 U/day (100 to 280 Units/day) saw significant A1c and insulin reductions4
Methods: Electronic medical records were queried to identify patients switched from previous insulin therapy to insulin delivery with V-Go. 104 patients were stratified by moderate baseline insulin doses (<100 U/day) or high baseline insulin doses (≥100 U/day)(n=38) and compared using TDD U/day and U/kg. A1c and average prescribed insulin dosing were collected at baseline and for 2 follow-up A1c results on V-Go (the VALIDATE study). TDD=total daily dose.
References: 4. Lajara R, Nikkel C. Poster: Using V-Go wearable insulin delivery device in patients prescribed high insulin doses: a comparison of clinical results between high and moderate insulin dose groups. Presented at: the Diabetes Technology Meeting, Bethesda MD. October 2015.